US20090192629A1 - Composition for an injectable bone mineral substitute material - Google Patents
Composition for an injectable bone mineral substitute material Download PDFInfo
- Publication number
- US20090192629A1 US20090192629A1 US12/219,543 US21954308A US2009192629A1 US 20090192629 A1 US20090192629 A1 US 20090192629A1 US 21954308 A US21954308 A US 21954308A US 2009192629 A1 US2009192629 A1 US 2009192629A1
- Authority
- US
- United States
- Prior art keywords
- aqueous liquid
- accelerator
- setting reaction
- composition
- reaction component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/0047—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L24/0052—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material with an inorganic matrix
- A61L24/0063—Phosphorus containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/02—Surgical adhesives or cements; Adhesives for colostomy devices containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/12—Phosphorus-containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/42—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix
- A61L27/425—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having an inorganic matrix of phosphorus containing material, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Definitions
- the present invention relates to an injectable composition for a bone mineral substitute material with the capability of being hardened in a body fluid in vivo. Furthermore, the invention relates to a method of producing such a material.
- bone mineral substitutes are used for the healing of bone defects and bone fractures, namely calcium sulphates, as for instance Plaster of Paris, calcium phosphates, as for instance hydroxylapatite, and polymers, as for instance polmethylmetacrylate (PMMA).
- calcium sulphates as for instance Plaster of Paris
- calcium phosphates as for instance hydroxylapatite
- PMMA polmethylmetacrylate
- Plaster of Paris Calcium sulphate (Plaster of Paris), CaSO 4 .1 ⁇ 2H 2 O, was one of the first materials investigated as a substitute for bone grafts. Studies have been undertaken since 1892 to demonstrate its acceptance by the tissues and rapid rate of resorbtion. It has been concluded that Plaster of Paris implanted in areas of subperiosteal bone produces no further untoward reaction in the tissue than normally is present in a fracture. Regeneration of bone in the area of subperiosteal resection occurs earlier than when an autogenous graft is used. Plaster of Paris does not stimulate osteogenesis in the absence of bone periosteum. The new bone growing into Plaster of Paris is normal bone. No side effects attributable to the implantation of Plaster of Paris have been noted in adjacent tissues or in distant organs. However, Plaster of Paris has the drawback of very long setting times, which constitutes problems at surgery.
- Another group of materials for substituting bone tissue in fracture sites and other bone defects is calcium phosphate cements. Due to their biocompatibility and their osteoconductivity they can be used for bone replacement and augmentation.
- Hydroxylapatite a crystalline substance which is the primary component of bone, is mainly used as a bone substitute, but is not strong enough for use under weight bearing conditions.
- hydroxylapatite cement forms a stable implant in respect of shape and volume over 12 months and has the same excellent tissue compatibility as exhibited by commercial ceramic hydroxylapatite preparations. Microscopic examination clearly demonstrated that hydroxylapatite cement was progressively ingrown by new bone over time.
- calcium phosphates can be obtained by means of sintering temperatures, above 1000° C. (Table 2). These calcium phosphates can not be obtained by precipitation in room or body temperature. However, they can be mixed with an aqueous solution alone or in combinations with other calcium phosphates to form a cement-like paste which will set with time.
- Bone mineral substitute materials can be used for preparing a paste which can be injected directly into a fracture site.
- the paste is injected into the void in the bone and, hardening, an implant is obtained which conforms to the contours of the gap and supports the cancellous bone.
- Both calcium sulphate and hydroxylapatite materials have been extensively investigated as a possible alternative to autogenous bone grafts to help restore osseous defects of bone and fixation of bone fracture.
- the hardened material is so similar in structure to the bone so that it can be gradually resorbed by the body and replaced by new bone growth. This process can be facilitated if the hardened cement is provided with pores, which can transport nutrients and provide growth sites for new bone formation.
- CN 1193614 shows a porous calcium phosphate bone cement for repairing human hard tissue.
- the cement contains pore-forming agent which maybe a non-toxic surfactant, or a non-toxic slightly soluble salt, acidic salt and alkaline salt.
- U.S. Pat. No. 4,619,655 is disclosed a bone mineral substitute material comprising a mixture of Plaster of Paris, i.e. calcium sulphate hemihydrate, and calcium phosphate ceramic particles, preferably composed of hydroxylapatite, or tricalcium phosphate or mixtures thereof.
- a bone mineral substitute material comprising a mixture of Plaster of Paris, i.e. calcium sulphate hemihydrate, and calcium phosphate ceramic particles, preferably composed of hydroxylapatite, or tricalcium phosphate or mixtures thereof.
- alloplasts composed of 50/50 mixtures of hydroxylapatite/Plaster of Paris were implanted into experimentally created defects in rat mandible, the Plaster of Paris was completely resorbed within a few weeks and replaced by connective tissue. The hydroxylapatite was not resorbed and some particles were eventually completely surrounded by bone. It was therefore concluded that the Plaster of Paris acted as a scaffold for the incorpor
- WO 9100252 shows a composition which is capable of hardening in blood within about 10-45 min.
- the composition comprises essentially calcium sulphate hemihydrate with small amounts of calcium sulphate dihydrate.
- Organic and inorganic materials, such as hydroxylapatite, can also be included in the composition. After hardening, particles of hydroxylapatite are obtained within a calcium sulphate cement. The calcium sulphate cement is dissolved rapidly by aqueous body fluids within four weeks, leaving solid particles of hydroxylapatite.
- Such particles of hydroxylapatite within a calcium sulphate cement are obtained by the method of WO 9117722.
- the composition for use as an animal implant comprises calcium sulphate hemihydrate, calcium phosphate, and sodium sulphate.
- the calcium phosphate is hydroxylapatite and the sodium sulphate enables the composition to be used in the presence of blood or other body fluids.
- the object of the invention is to provide an injectable composition for a bone mineral substitute material with the capability of being hardened in a body fluid in vivo, which hardens during surgery with accompanying early control of fracture fragment movement as well as provides a stable lasting implant over a year with high mechanical strength, and which during this later period presents a porous as well as irregular structure for bone in growth.
- a further object of the present invention is to provide such an improved injectable bone mineral substitute for filling defects in osteoporotic bone and for additional fracture fixation in substantially cancellous bone which does not exhibit the drawbacks of high viscosity at delivery and low fracture toughness.
- Still another object of the invention is to provide an injectable bone mineral substitute having excellent biocompatibility, favorable biological and rheological properties.
- the bone mineral substitute should also be biodegradable and be possible to sterilize by radiation or gas without suffering a significant deterioration in properties.
- composition which comprises two types of bone cement materials, which both are subjected to a hardening reaction in contact with water.
- a cement of hardened calcium sulphate (gypsum) will remain set in a dry environment. In a wet environment, such as in a Body Simulated Solution, this material will immediately start to disintegrate. Thus, an implanted material with reduced strength will be obtained in the body. The solid material obtained will start to degrade, eventually within 1-2 days.
- saline in order to induce a setting (hardening) reaction in a Body Simulated Solution or in a body with its blood, saline can be used. By using saline a setting will be obtained immediately under any conditions, but the implant obtained will still degrade quite rapidly.
- the second reaction in which a calcium phosphate is hardened (cemented) to a calcium phosphate cement in the presence of water, will take longer time—about 18 h or more—in order to set to a high strength material. During this period of time the already set sulphate will confer an initial strength to the implant, and when the setting reaction of tricalcium phosphate to a high strength material is completed, a final strength will be obtained, which lasts for months or years.
- calcium phosphate cement refers to the recognized definition (S. E. Gruninger, C. Siew, L. C Chow, A. O'Young, N. K. Tsao, W. B. Brown, J. Dent. Res. 63 (1984) 200) of a reaction product of a powder or a mixture of powders which—after mixing with water or an aqueous solution to a paste—at a temperature around room temperature or body temperature react with the formation of a precipitate, which contains crystals of one or more calcium phosphates and which sets by the entanglement of the crystals within the precipitate.
- different calcium phosphate products can be obtained during the setting reaction in dependence on the component(s) of the powders used for the paste inventive injectable composition for a bone mineral substitute material.
- FIG. 1 shows the effects of ⁇ -tricalcium phosphate on compressive strength
- FIG. 2 shows the effects of the content of calcium sulphate dehydrate on the injection time
- FIG. 3 shows the effects of the water content and the content of calcium sulphate dehydrate on the setting time.
- the inventive injectable composition for a bone mineral substitute material comprises a dry powder mixed with an aqueous liquid.
- a main requirement on such a material is its setting time, which should be within 5-12 minutes. Additionally, the viscosity of the material should be adapted to render it injectable into the bone for 1-5 minutes after the beginning of the mixing procedure.
- the evaluated materials comprised calcium sulphate hemihydrate, also known as Plaster of Paris. It was found that the addition of a small amount of finely ground already reacted calcium sulphate dihydrate, CaSO 4 .2H 2 O, had a decisive impact on the setting time and the injectable time of the bone mineral substitute. Due to the addition of an accelerator the setting time period was considerably shortened while the injectable time was still long enough to make it possible to inject the material of the invention into e.g. a bone cavity. It is assumed that other accelerators and mixtures of accelerators may be used, e.g. starch, mixtures of calcium sulphate dihydrate and lignosulphate, calcium sulphate dihydrates having composite coatings, etc.
- the first group consists of calcium phosphates, which are transformed into hydroxylapatite by a hydrolysis process in an aqueous solution (eq. 1-5).
- Precipitated hydroxylapatite is the least soluble calcium phosphate at pH over 4.2. This means that any other calcium phosphate present in an aqueous solution at this pH range will tend to dissolve, with the precipitation of PHA as a product.
- This hydrolysis process (Ca(OH) 2 —H 3 PO 4 —H 2 O) is very slow due to a decrease in supersaturation as the reaction proceeds.
- the only calcium phosphate which can react via a hydrolysis process to an apatite without the formation of sub-products is ⁇ -tricalcium phosphate (eq. 6)
- the apatite formed in this reaction is a calcium deficient hydroxylapatite.
- the second group of reactions to a hydroxylapatite i.e. precipitated hydroxylapatite (PHA) or calcium deficient hydroxylapatite (CDHA)
- PHA precipitated hydroxylapatite
- CDHA calcium deficient hydroxylapatite
- TTCP is the only calcium phosphate with Ca/P ratio above 1.67.
- this substance can be mixed with other calcium phosphates with lower Ca/P ratio to obtain PHA or CDHA without the formation of acids or bases as by-products.
- any calcium phosphate more acid than PHA can react directly with TTCP to form HA or CDHA according to the following chemical reactions.
- DCPD is formed as an intermediate reaction product, but with PHA or CDHA at the end of the reaction.
- Reactions (13), (14), and (15) are all very slow.
- by using the formulas (9)-(12) it is possible to produce a cement which sets and hardens with time at room or body temperature and at a neutral pH.
- PHA as the final hardened product by using mixtures of calcium phosphates with a Ca/P ratio of less than 1.67. This is accomplished by using additional calcium sources, such as Ca(OH) 2 or CaCO 3 , instead of TTCP.
- additional calcium sources such as Ca(OH) 2 or CaCO 3
- TTCP calcium sources
- One example is the reaction ⁇ -TCP+DCPD+CaCO 3 ⁇ PHA. Initially formed crystals of PHA from a reaction between CDPD and CaCO 3 function as binders between ⁇ -TCP particles. When DCPD is consumed the reaction continues between the remaining calcium carbonate and ⁇ -TCP with the formation of PHA. However, it seems that the latter process has a detrimental effect on the mechanical strength of the cement.
- the calcium phosphate with the capability of being hardened to a calcium phosphate cement when reacting with an aqueous liquid is tricalcium phosphate (TCP), tetracalcium phosphate (TTCP), anhydrous dicalcium phosphate, monocalcium phosphate monohydrate (MCPM), dicalcium phosphate dihydrate (DCPD), or octocalcium phosphate (OCP).
- TCP tricalcium phosphate
- TTCP tetracalcium phosphate
- MCPM monocalcium phosphate monohydrate
- DCPD dicalcium phosphate dihydrate
- OCP octocalcium phosphate
- the calcium phosphate is ⁇ -tricalcium phosphate.
- the calcium sulphate hemihydrate in the composition according to the invention should comprise 2-80 wt %, preferably 10-30 wt % of the dry powder to be mixed with an aqueous liquid.
- the calcium phosphate to be hardened to a calcium phosphate cement should comprise 10-98 wt %, preferably 70-90 wt % of the dry powder.
- the aqueous liquid should comprise between 0.1 and 2 ml, preferably between 0.5 and 1 ml per gram powder.
- a high strength implant material will be obtained initially.
- the fast setting calcium sulphate material will be formed within a block of a slow setting material, i.e. the calcium phosphate cement.
- a slow setting material i.e. the calcium phosphate cement.
- Both reactions in the inventive composition can be controlled by including an accelerator or a retarder. By using seed particles, the processes can be accelerated.
- the calcium sulphate hemihydrate will set rapidly, i.e. within 10 min.
- Particulate calcium sulphate dihydrate is a suitable accelerator for this reaction, the particle size being less than 1 mm.
- a more efficient reaction is obtained if the particulate calcium sulphate dihydrate has a particle size of less than 150 ⁇ m, preferably less than 100 ⁇ m, and most preferable less than 50 ⁇ m.
- the particulate calcium sulphate dehydrate should comprise between 0.1 and 10 wt %, preferably between 0.1 and 2 wt % of the calcium sulphate hemihydrate which is to react with an aqueous liquid.
- the accelerator should be adapted so that a set material is obtained within 15 min, preferably within 8 min, which has a threshold strength of about 30 MPa in a clinical situation.
- the particulate calcium sulphate dihydrate is ⁇ -calcium sulphate dehydrate.
- the second reaction of a calcium phosphate to a calcium phosphate cement sets slowly, but can be controlled to set within 18 h as a bone mineral substitute material with a strength of about 30 MPa. This can be accomplished by adding hardened particulate calcium phosphate cement to the inventive composition.
- the hardened calcium phosphate cement can be hydroxylapatite (HA), preferably precipitated hydroxylapatite (PHA), tricalcium phosphate (TCP), or a mixture thereof. It should have a Ca/P ratio between 1.5 and 2.
- the particulate calcium phosphate cement should have a particle size which is less than 20 ⁇ m, preferably less than 10 ⁇ m and comprise between 0.1 and 10 wt %, preferably between 0.5 and 5 wt % of the calcium phosphate which is to react with an aqueous liquid.
- the reaction of calcium phosphate to a calcium phosphate cement can also be accelerated by a phosphate salt, for example disodium hydrogen phosphate (Na 2 HPO 4 ), which is dissolved in the aqueous liquid.
- a phosphate salt for example disodium hydrogen phosphate (Na 2 HPO 4 )
- the accelerator should be present in the aqueous liquid at concentrations of 0.1-10 wt %, preferably 1-5 wt %.
- the two types of accelerator for the reaction of calcium phosphate to calcium phosphate cement can be used either separately or in combination.
- the aqueous liquid can be distilled water or a balanced salt solution, such as PBS, PBSS, GBSS, EBSS, HBSS, or SBF.
- a balanced salt solution such as PBS, PBSS, GBSS, EBSS, HBSS, or SBF.
- the injectability of the composition according to the invention can be improved in several ways. It has surprisingly been shown that a pH reducing component can be added to the inventive composition, the injectability thereof being improved.
- a pH reducing component is for example ascorbic acid or citric acid. These acids are included in the sterile liquid or the sterile powder of the composition in amounts of 0.1-5 wt %, preferably 0.5-2 wt %.
- Another way to improve the injectability of the composition is to add a biologically compatible oil.
- the concentration of the oil should be between 0.1 and 5 wt %, preferably between 0.5 and 2 wt %.
- a suitable oil to be used in the inventive composition is vitamin E.
- the oil can either be intermixed with the sterile powder or included in the sterile liquid of the composition.
- the addition of a small amount of already reacted calcium sulphate dihydrate had an effect on the injectable time of the bone mineral substitute.
- the injectability of the composition could be improved.
- 95% of the hemihydrate can be replaced.
- 50-90% of the hemihydrate is replaced by the dihydrate, most preferred 80-90%.
- the bone mineral substitute material obtained with the inventive composition it is possible to further include additional substances, e.g. growth factors, anti-cancer substances, antioxidants and/or antibiotics, etc.
- additional substances e.g. growth factors, anti-cancer substances, antioxidants and/or antibiotics, etc.
- Antibiotic containing bone cement is already known and it has been shown that addition of antibiotics to synthetic hydroxylapatite and cancellous bone releases said antibiotics in a concentration sufficient for treating bone infections when said substances are administered into the bone.
- An efficient mixing system must be available in order to prepare the composition according to the invention.
- the mixing can take place in a conventional cement mixing system and the composition is injected by means of a convenient delivery system.
- the mixing container is preferably of that type which can suck the aqueous component into the powder component (German Patent 4409610).
- This PrepackTM system is a closed mixing system for delivery in combination with prepacked components in a flexible foil bag.
- Other mixing devices can of course also be used, for example two interconnected soft bags which can be adapted to a delivering cylinder.
- the formation of air bubbles in the composition can be prevented by mixing the composition under conditions of subatmospheric pressure, e.g. in vacuo.
- subatmospheric pressure e.g. in vacuo.
- an atmospheric pressure can also be used.
- the powder component of the composition is sterilized by means of radiation before it is mixed with the sterile liquid component.
- the injectable time and the setting time of pure calcium sulphate hemihydrate were determined to be more than 10 and 20 minutes, respectively.
- the injectable time and the setting time of a mixture of calcium sulphate hemihydrate, and hydroxylapatite were also determined to be more than 10 and 20 minutes, respectively.
- the injectable time (IT) and the setting time (SI) were studied for the first reaction of a calcium sulphate hemihydrate to calcium sulphate dihydrate in the presence of a passive additive. Twenty different mixtures of calcium sulphate hemihydrate, hydroxylapatite (HA) and accelerator (Acc) were evaluated, which had different ratios of hydroxylapatite and accelerator, see Table 3.
- the setting time was determined by a mechanical test. A metallic rod having a weight of 23 g, a diameter of 10 mm and a length of 35 mm was dropped from a height of 35 mm. The time when the rod did not leave any mark on the sample was registered as the setting time.
- CSH calcium sulphate hemihydrate
- the two powders were mixed together mechanically during 5 min. Then, the liquid was added to the powder at a liquid to powder (L/P) ratio of 0.32 ml.g ⁇ 1 .
- the liquid contained 2.5 wt % Na 2 HPO 4 as an accelerator.
- crystals are formed when calcium sulphate hemihydrate and calcium phosphate, respectively, react with water in the setting reactions. Initially, crystal nuclei are created and the final crystal structure is then formed by growth from the nuclei. By adding already formed crystals of set material, the nucleation step in the setting process is already completed, which will decrease the time needed to crystallize the material and make it hard. The crystals will grow directly from particles of added calcium sulphate dihydrate and hydroxylapatite, respectively. Thus, these added particles of set material will act as accelerators in the setting reactions.
- the effects of the content of calcium sulphate dihydrate on the injection time is shown in FIG. 2 .
- the liquid/powder (L/P) ratio is 0.4 ml/g.
- the limit of injection time was defined when the load reached N, which is comparable to the highest force by hand at which injection was possible.
- the form of the calcium sulphate hemihydrate is of importance.
- ⁇ -Calcium sulphate hemihydrate ( ⁇ -CaSO 4 .1 ⁇ 2H 2 O) is advantageous to use because of its mechanical strength.
- ⁇ -CaSO 4 .1 ⁇ 2H 2 O has a compressive strength of 40.4 MPa compared with 14 MPa for ⁇ - ⁇ -CaSO 4 .1 ⁇ 2H 2 O.
- the degradation rate of calcium sulphate with 40 wt % hydroxylapatite was investigated.
- the material was placed in a Simulated Body Fluid as well as muscle pockets in rats.
- the mechanical strength and size of the block obtained were investigated with time as a biodegradation index.
- Compressive strength testing was performed using an MTS and Instron 8511.20 testing equipment. After harvesting the materials, the samples were directly placed between self-levelling platens and compressed at 1 mm min ⁇ 1 until failure at room temperature.
- a caliper measured the volume of the block of material.
- Calcium sulphate hemihydrate (CaSO 4 .1 ⁇ 2H 2 O) was mixed with 40 wt % hydroxylapatite powder (Ca 10 (PO 4 ) 6 (OH) 2 ; HA). The mixture of POP-HA was sintered and quenched in air. An accelerator (a calcium sulphate) was added at 0.4 wt % to the POP-HA, and the dry powder material was sterilized by gamma-irradiation.
- a cement was prepared by mixing the powder with distilled water at a L/P ratio of 0.25 ml/g. Materials were prepared, which contained calcium sulphate or calcium sulphate+hydroxylapatite. After mixing, the cement was injected into a PFTE mould and allowed to set. The samples were cylindrical with diameter of 4 mm and height of 8 mm. Once set, the samples are inserted into muscle pockets of rats.
- Sprague-Dawley rats weighing around 200 g were used and kept in animal facilities for 1 week before use. The animals were fed a standard laboratory diet. All rats were anesthetized with peritoneal injections of 0.5-0.6 ml of a solution containing 1 ml pentobarbital (60 mg/ml), 2 ml diazepam (5 mg/ml), and 1 ml saline (0.15 M). The implants were inserted in muscles of the rats. Nine rats were used for each period studied. The rats were killed by a peritoneal injection of an overdose of pentobarbital at 1 or 4 weeks after implantation.
- Table 6 shows the volume of remaining cylinder material (Mean ⁇ SE) in rat muscles after an incubation of 1 or 4 weeks.
- the original volume of the cylinder material was 100 mm 3 .
- Statistic analysis was performed by using the one way ANOVA method and Student's t-test. All results obtained exhibited a high statistical significance (p ⁇ 0.0001).
- the implanted material comprising calcium sulphate and hydroxylapatite was rapidly degraded within one week in both Simulated Body Fluid and in rats.
- the rate of degradation was the same in Simulated Body Fluid or muscles pockets, indicating that only one method is needed in order to demonstrate the degradation rate.
- tests of the combined sulphate and phosphate material exhibit biodegradation in vitro and in vivo as well as hardening of both components with good results with reference to injectability and setting.
Abstract
Description
- The present invention relates to an injectable composition for a bone mineral substitute material with the capability of being hardened in a body fluid in vivo. Furthermore, the invention relates to a method of producing such a material.
- During the last decade, the number of fractures related to osteoporosis, i.e. reduced bone mass and changes in microstructure leading to an increased risk of bone fractures, has almost doubled. Due to the continuously increasing average life time it is estimated that by 2020 people over 60 years of age will represent 25% of Europe's population and that 40% of all women over 50 years of age will suffer from an osteoporotic fracture.
- With the aim to reduce or eliminate the need for bone grafting, research has been made to find a suitable artificial bone mineral substitute. Presently, at least the following bone mineral substitutes are used for the healing of bone defects and bone fractures, namely calcium sulphates, as for instance Plaster of Paris, calcium phosphates, as for instance hydroxylapatite, and polymers, as for instance polmethylmetacrylate (PMMA).
- Calcium sulphate (Plaster of Paris), CaSO4.½H2O, was one of the first materials investigated as a substitute for bone grafts. Studies have been undertaken since 1892 to demonstrate its acceptance by the tissues and rapid rate of resorbtion. It has been concluded that Plaster of Paris implanted in areas of subperiosteal bone produces no further untoward reaction in the tissue than normally is present in a fracture. Regeneration of bone in the area of subperiosteal resection occurs earlier than when an autogenous graft is used. Plaster of Paris does not stimulate osteogenesis in the absence of bone periosteum. The new bone growing into Plaster of Paris is normal bone. No side effects attributable to the implantation of Plaster of Paris have been noted in adjacent tissues or in distant organs. However, Plaster of Paris has the drawback of very long setting times, which constitutes problems at surgery.
- Another group of materials for substituting bone tissue in fracture sites and other bone defects is calcium phosphate cements. Due to their biocompatibility and their osteoconductivity they can be used for bone replacement and augmentation.
- Hydroxylapatite, a crystalline substance which is the primary component of bone, is mainly used as a bone substitute, but is not strong enough for use under weight bearing conditions. Experiments have shown that hydroxylapatite cement forms a stable implant in respect of shape and volume over 12 months and has the same excellent tissue compatibility as exhibited by commercial ceramic hydroxylapatite preparations. Microscopic examination clearly demonstrated that hydroxylapatite cement was progressively ingrown by new bone over time.
- Although the ideal is to achieve hydroxylapatite, there are also apatite-like calcium phosphates which can be obtained as potential bone substitutes. In Table 1 calcium phosphates are presented which are formed by a spontaneous precipitation at room or body temperature, as well as the pH range, within which these components are stable.
-
TABLE 1 Calcium phosphates obtained by precipitation at room or body temperature Ca/P Formula Name pH 0.5 Ca(H2PO4)•H2O MCPM 0.0-2.0 1 CaHPO4•2H2O DCPD 2.0-6.0 1.33 Ca8(HPO4)2, (PO4)4•5H2O OCP 5.5-7.0 1.5 Ca9(HPO4)(PO4)5OH CDHA 6.5-9.5 1.67 Ca5(PO4)3OH PHA 9.-5-12 - Other calcium phosphates can be obtained by means of sintering temperatures, above 1000° C. (Table 2). These calcium phosphates can not be obtained by precipitation in room or body temperature. However, they can be mixed with an aqueous solution alone or in combinations with other calcium phosphates to form a cement-like paste which will set with time.
-
TABLE 2 Components forming calcium phosphate cements Ca/P Compound Formula Name 1.5 α-tricalcium phosphate α-Ca3(PO4)2 α-TCP 1.5 β-tricalcium β-Ca3(PO4)2 β-TCP 1.67 Sintered hydroxylapatite Ca10(PO4)6(OH)2 SHA 2.0 Tetracalcium phosphate Ca4(PO4)2O TTCP - Bone mineral substitute materials can be used for preparing a paste which can be injected directly into a fracture site. The paste is injected into the void in the bone and, hardening, an implant is obtained which conforms to the contours of the gap and supports the cancellous bone. Both calcium sulphate and hydroxylapatite materials have been extensively investigated as a possible alternative to autogenous bone grafts to help restore osseous defects of bone and fixation of bone fracture.
- In this connection it is important that a complete stability is obtained as quickly as possible during or after surgery in order to prevent motions at site of healing. This especially applies to fractures, but also when filling of a bone cavity or replacing bone lost during tumor removal the healing is inhibited by movements and the in-growth of new bone is prevented.
- It is also of importance that the hardened material is so similar in structure to the bone so that it can be gradually resorbed by the body and replaced by new bone growth. This process can be facilitated if the hardened cement is provided with pores, which can transport nutrients and provide growth sites for new bone formation.
- M. Bohner et al. disclosed at the Sixth World Biomaterials Congress Transactions (15-20/5 2000) a method to obtain an open macroporous calcium phosphate block by using an emulsion of a hydrophobic lipid (oil) in an aqueous calcium phosphate cement paste or an emulsion of an aqueous calcium phosphate cement paste in oil. After setting, the cement block was sintered at 1250° C. for 4 hours. Likewise, CN 1193614 shows a porous calcium phosphate bone cement for repairing human hard tissue. The cement contains pore-forming agent which maybe a non-toxic surfactant, or a non-toxic slightly soluble salt, acidic salt and alkaline salt.
- Studies have also been made on mixtures of the above mentioned bone mineral substitute materials. In U.S. Pat. No. 4,619,655 is disclosed a bone mineral substitute material comprising a mixture of Plaster of Paris, i.e. calcium sulphate hemihydrate, and calcium phosphate ceramic particles, preferably composed of hydroxylapatite, or tricalcium phosphate or mixtures thereof. According to U.S. Pat. No. 4,619,655 tests show that when alloplasts composed of 50/50 mixtures of hydroxylapatite/Plaster of Paris were implanted into experimentally created defects in rat mandible, the Plaster of Paris was completely resorbed within a few weeks and replaced by connective tissue. The hydroxylapatite was not resorbed and some particles were eventually completely surrounded by bone. It was therefore concluded that the Plaster of Paris acted as a scaffold for the incorporation of hydroxylapatite into bone.
- A recent study presented on the “Combined Orthopaedic Research Societies Meeting”, Sep. 28-30, 1998, Hamamatsu, Japan, also shows additional tests relating to mixtures of Plaster of Paris and hydroxylapatite. According to this study a combination of hydroxylapatite particles and Plaster of Paris had a viscosity which allowed an easy placement of the implant material and prevented migration of hydroxylapatite particles into surrounding tissues during and after implantation. The experiments showed that Plaster of Paris was absorbed in relatively short time, was easily manipulated with hydroxylapatite particles, and did not interfere with the process of bone healing.
- WO 9100252 shows a composition which is capable of hardening in blood within about 10-45 min. The composition comprises essentially calcium sulphate hemihydrate with small amounts of calcium sulphate dihydrate. Organic and inorganic materials, such as hydroxylapatite, can also be included in the composition. After hardening, particles of hydroxylapatite are obtained within a calcium sulphate cement. The calcium sulphate cement is dissolved rapidly by aqueous body fluids within four weeks, leaving solid particles of hydroxylapatite.
- Likewise, such particles of hydroxylapatite within a calcium sulphate cement are obtained by the method of WO 9117722. The composition for use as an animal implant comprises calcium sulphate hemihydrate, calcium phosphate, and sodium sulphate. The calcium phosphate is hydroxylapatite and the sodium sulphate enables the composition to be used in the presence of blood or other body fluids.
- The object of the invention is to provide an injectable composition for a bone mineral substitute material with the capability of being hardened in a body fluid in vivo, which hardens during surgery with accompanying early control of fracture fragment movement as well as provides a stable lasting implant over a year with high mechanical strength, and which during this later period presents a porous as well as irregular structure for bone in growth.
- A further object of the present invention is to provide such an improved injectable bone mineral substitute for filling defects in osteoporotic bone and for additional fracture fixation in substantially cancellous bone which does not exhibit the drawbacks of high viscosity at delivery and low fracture toughness.
- Still another object of the invention is to provide an injectable bone mineral substitute having excellent biocompatibility, favorable biological and rheological properties. The bone mineral substitute should also be biodegradable and be possible to sterilize by radiation or gas without suffering a significant deterioration in properties.
- In order to achieve these objects the injectable composition according to the invention has been given the characterizing features of
claim 1. - According to the invention a composition is provided which comprises two types of bone cement materials, which both are subjected to a hardening reaction in contact with water.
- A cement of hardened calcium sulphate (gypsum) will remain set in a dry environment. In a wet environment, such as in a Body Simulated Solution, this material will immediately start to disintegrate. Thus, an implanted material with reduced strength will be obtained in the body. The solid material obtained will start to degrade, eventually within 1-2 days.
- On the other hand, in order to induce a setting (hardening) reaction in a Body Simulated Solution or in a body with its blood, saline can be used. By using saline a setting will be obtained immediately under any conditions, but the implant obtained will still degrade quite rapidly.
- The second reaction, in which a calcium phosphate is hardened (cemented) to a calcium phosphate cement in the presence of water, will take longer time—about 18 h or more—in order to set to a high strength material. During this period of time the already set sulphate will confer an initial strength to the implant, and when the setting reaction of tricalcium phosphate to a high strength material is completed, a final strength will be obtained, which lasts for months or years.
- In this connection the term “calcium phosphate cement” refers to the recognized definition (S. E. Gruninger, C. Siew, L. C Chow, A. O'Young, N. K. Tsao, W. B. Brown, J. Dent. Res. 63 (1984) 200) of a reaction product of a powder or a mixture of powders which—after mixing with water or an aqueous solution to a paste—at a temperature around room temperature or body temperature react with the formation of a precipitate, which contains crystals of one or more calcium phosphates and which sets by the entanglement of the crystals within the precipitate. Thus, different calcium phosphate products (calcium phosphate cements) can be obtained during the setting reaction in dependence on the component(s) of the powders used for the paste inventive injectable composition for a bone mineral substitute material.
- The invention will now be explained in more detail, reference being made to the accompanying drawings, in which
-
FIG. 1 shows the effects of α-tricalcium phosphate on compressive strength; -
FIG. 2 shows the effects of the content of calcium sulphate dehydrate on the injection time; and -
FIG. 3 shows the effects of the water content and the content of calcium sulphate dehydrate on the setting time. - In order to accomplish an injectable bone mineral substitute material having improved characteristics, tests were made with the object to evaluate the effects of particle size, water content and accelerator on the viscosity, setting time and porosity of the injectable bone mineral substitute material of the invention.
- The inventive injectable composition for a bone mineral substitute material comprises a dry powder mixed with an aqueous liquid. A main requirement on such a material is its setting time, which should be within 5-12 minutes. Additionally, the viscosity of the material should be adapted to render it injectable into the bone for 1-5 minutes after the beginning of the mixing procedure.
- The evaluated materials comprised calcium sulphate hemihydrate, also known as Plaster of Paris. It was found that the addition of a small amount of finely ground already reacted calcium sulphate dihydrate, CaSO4.2H2O, had a decisive impact on the setting time and the injectable time of the bone mineral substitute. Due to the addition of an accelerator the setting time period was considerably shortened while the injectable time was still long enough to make it possible to inject the material of the invention into e.g. a bone cavity. It is assumed that other accelerators and mixtures of accelerators may be used, e.g. starch, mixtures of calcium sulphate dihydrate and lignosulphate, calcium sulphate dihydrates having composite coatings, etc.
- Those reactions which forms hydroxylapatite, i.e. precipitated hydroxylapatite (PHA) or calcium deficient hydroxylapatite (CDHA), can be classified into three groups. The first group consists of calcium phosphates, which are transformed into hydroxylapatite by a hydrolysis process in an aqueous solution (eq. 1-5).
-
5Ca(H2PO4)—H2O→Ca5(PO4)3OH+7H3PO4+4H2O (1) -
5CaHPO4.2H2O→Ca5(PO4)3OH+2H3PO4+9H2O (2) -
5Ca8H2(PO4)6.5H2O→8Ca5(PO4)3OH+6H3PO4+17H2O (3) -
5Ca3(PO4)2+3H2O→3Ca5(PO4)3OH+H3PO4 (4) -
3Ca4(PO4)2O+3H2O→2Ca5(PO4)3OH+Ca(OH)2 (5) - Precipitated hydroxylapatite is the least soluble calcium phosphate at pH over 4.2. This means that any other calcium phosphate present in an aqueous solution at this pH range will tend to dissolve, with the precipitation of PHA as a product. This hydrolysis process (Ca(OH)2—H3PO4—H2O) is very slow due to a decrease in supersaturation as the reaction proceeds.
- The only calcium phosphate which can react via a hydrolysis process to an apatite without the formation of sub-products is α-tricalcium phosphate (eq. 6), and the apatite formed in this reaction is a calcium deficient hydroxylapatite.
-
3α-Ca3(PO4)2+H2O→Ca9(HPO4)(PO4)5OH (6) - The second group of reactions to a hydroxylapatite, i.e. precipitated hydroxylapatite (PHA) or calcium deficient hydroxylapatite (CDHA), is the combinations between TTCP and other calcium phosphates. TTCP is the only calcium phosphate with Ca/P ratio above 1.67. Thus, this substance can be mixed with other calcium phosphates with lower Ca/P ratio to obtain PHA or CDHA without the formation of acids or bases as by-products. Theoretically, any calcium phosphate more acid than PHA can react directly with TTCP to form HA or CDHA according to the following chemical reactions.
-
7Ca4(PO4)2O+2Ca(H2PO4)2.H2O→6Ca5(PO4)3OH+3H2O (7) -
2Ca4(PO4)2O+Ca(H2PO4)2.H2O→Ca9(HPO4)(PO4)5OH+2H2O (8) -
Ca4(PO4)2O+CaHPO4.2H2O→Ca5(PO4)3OH+2H2O (9) -
3Ca4(PO4)2O+6CaHPO4.2H2O→2Ca9(HPO4)(PO4)5OH+13H2O (10) -
Ca4(PO4)2O+CaHPO4→Ca5(PO4)3OH (11) -
3Ca4(PO4)2O+6CaHPO4→2Ca9(HPO4)(PO4)5OH+H2O (12) -
3Ca4(PO4)2O+Ca9H2(PO4)6.5H2O→4Ca5(PO4)3OH+4H2O (13) -
3Ca4(PO4)2O+3Ca9H2(PO4)6.5H2O→4Ca9(HPO4)(PO4)5OH+14H2O (14) -
Ca4(PO4)2O+2Ca3(PO4)2+H2O→Ca5(PO4)3OH (15) - In equations (7) and (8) DCPD is formed as an intermediate reaction product, but with PHA or CDHA at the end of the reaction. Reactions (13), (14), and (15) are all very slow. However, by using the formulas (9)-(12) it is possible to produce a cement which sets and hardens with time at room or body temperature and at a neutral pH.
- It is also possible to form PHA as the final hardened product by using mixtures of calcium phosphates with a Ca/P ratio of less than 1.67. This is accomplished by using additional calcium sources, such as Ca(OH)2 or CaCO3, instead of TTCP. One example is the reaction β-TCP+DCPD+CaCO3→PHA. Initially formed crystals of PHA from a reaction between CDPD and CaCO3 function as binders between β-TCP particles. When DCPD is consumed the reaction continues between the remaining calcium carbonate and β-TCP with the formation of PHA. However, it seems that the latter process has a detrimental effect on the mechanical strength of the cement.
- It is preferred that the calcium phosphate with the capability of being hardened to a calcium phosphate cement when reacting with an aqueous liquid is tricalcium phosphate (TCP), tetracalcium phosphate (TTCP), anhydrous dicalcium phosphate, monocalcium phosphate monohydrate (MCPM), dicalcium phosphate dihydrate (DCPD), or octocalcium phosphate (OCP). Preferably, the calcium phosphate is α-tricalcium phosphate.
- In order to confer an initial strength to a bone mineral substitute material the calcium sulphate hemihydrate in the composition according to the invention should comprise 2-80 wt %, preferably 10-30 wt % of the dry powder to be mixed with an aqueous liquid. Likewise, the calcium phosphate to be hardened to a calcium phosphate cement should comprise 10-98 wt %, preferably 70-90 wt % of the dry powder. In the composition, the aqueous liquid should comprise between 0.1 and 2 ml, preferably between 0.5 and 1 ml per gram powder.
- By preferably using particulate reaction components in the inventive composition, a high strength implant material will be obtained initially. The fast setting calcium sulphate material will be formed within a block of a slow setting material, i.e. the calcium phosphate cement. Thus, when initial strength decreases the second strength increases, and its final strength will be maintained within the body. Pores, holes and cavities will gradually be formed as the sulphate degrades, which acts like lacuna, and the finally set and hardened implant of a high strength material will look like a normal bone.
- Both reactions in the inventive composition can be controlled by including an accelerator or a retarder. By using seed particles, the processes can be accelerated.
- If such an accelerator is added, the calcium sulphate hemihydrate will set rapidly, i.e. within 10 min. Particulate calcium sulphate dihydrate is a suitable accelerator for this reaction, the particle size being less than 1 mm. A more efficient reaction is obtained if the particulate calcium sulphate dihydrate has a particle size of less than 150 μm, preferably less than 100 μm, and most preferable less than 50 μm. The particulate calcium sulphate dehydrate should comprise between 0.1 and 10 wt %, preferably between 0.1 and 2 wt % of the calcium sulphate hemihydrate which is to react with an aqueous liquid. The accelerator should be adapted so that a set material is obtained within 15 min, preferably within 8 min, which has a threshold strength of about 30 MPa in a clinical situation. Preferably, the particulate calcium sulphate dihydrate is α-calcium sulphate dehydrate.
- The second reaction of a calcium phosphate to a calcium phosphate cement sets slowly, but can be controlled to set within 18 h as a bone mineral substitute material with a strength of about 30 MPa. This can be accomplished by adding hardened particulate calcium phosphate cement to the inventive composition. The hardened calcium phosphate cement can be hydroxylapatite (HA), preferably precipitated hydroxylapatite (PHA), tricalcium phosphate (TCP), or a mixture thereof. It should have a Ca/P ratio between 1.5 and 2. The particulate calcium phosphate cement should have a particle size which is less than 20 μm, preferably less than 10 μm and comprise between 0.1 and 10 wt %, preferably between 0.5 and 5 wt % of the calcium phosphate which is to react with an aqueous liquid.
- The reaction of calcium phosphate to a calcium phosphate cement can also be accelerated by a phosphate salt, for example disodium hydrogen phosphate (Na2HPO4), which is dissolved in the aqueous liquid. In this case, the accelerator should be present in the aqueous liquid at concentrations of 0.1-10 wt %, preferably 1-5 wt %.
- The two types of accelerator for the reaction of calcium phosphate to calcium phosphate cement can be used either separately or in combination.
- In the composition according to the invention the aqueous liquid can be distilled water or a balanced salt solution, such as PBS, PBSS, GBSS, EBSS, HBSS, or SBF.
- The injectability of the composition according to the invention can be improved in several ways. It has surprisingly been shown that a pH reducing component can be added to the inventive composition, the injectability thereof being improved. Such a pH reducing component is for example ascorbic acid or citric acid. These acids are included in the sterile liquid or the sterile powder of the composition in amounts of 0.1-5 wt %, preferably 0.5-2 wt %.
- Another way to improve the injectability of the composition is to add a biologically compatible oil. The concentration of the oil should be between 0.1 and 5 wt %, preferably between 0.5 and 2 wt %. A suitable oil to be used in the inventive composition is vitamin E. The oil can either be intermixed with the sterile powder or included in the sterile liquid of the composition.
- As stated above, the addition of a small amount of already reacted calcium sulphate dihydrate had an effect on the injectable time of the bone mineral substitute. Thus, by replacing some of the non-reacted calcium sulphate hemihydrate with reacted calcium sulphate dihydrate, the injectability of the composition could be improved. As much as 95% of the hemihydrate can be replaced. Preferably, 50-90% of the hemihydrate is replaced by the dihydrate, most preferred 80-90%.
- In order to further improve the bone mineral substitute material obtained with the inventive composition it is possible to further include additional substances, e.g. growth factors, anti-cancer substances, antioxidants and/or antibiotics, etc. Antibiotic containing bone cement is already known and it has been shown that addition of antibiotics to synthetic hydroxylapatite and cancellous bone releases said antibiotics in a concentration sufficient for treating bone infections when said substances are administered into the bone.
- An efficient mixing system must be available in order to prepare the composition according to the invention. The mixing can take place in a conventional cement mixing system and the composition is injected by means of a convenient delivery system. The mixing container is preferably of that type which can suck the aqueous component into the powder component (German Patent 4409610). This Prepack™ system is a closed mixing system for delivery in combination with prepacked components in a flexible foil bag. Other mixing devices can of course also be used, for example two interconnected soft bags which can be adapted to a delivering cylinder.
- The formation of air bubbles in the composition, which can interfere with the hardening reaction of the calcium sulphate hemihydrate and result in a decreased initial mechanical strength of the implanted material during surgery, can be prevented by mixing the composition under conditions of subatmospheric pressure, e.g. in vacuo. However, an atmospheric pressure can also be used. Preferably, the powder component of the composition is sterilized by means of radiation before it is mixed with the sterile liquid component.
- The invention will now be further described and illustrated by, reference to the following examples. It should be noted, however, that these examples should not be construed as limiting the invention in any way.
- As a control test the injectable time and the setting time of pure calcium sulphate hemihydrate were determined to be more than 10 and 20 minutes, respectively.
- As a second control test the injectable time and the setting time of a mixture of calcium sulphate hemihydrate, and hydroxylapatite were also determined to be more than 10 and 20 minutes, respectively.
- The injectable time (IT) and the setting time (SI) were studied for the first reaction of a calcium sulphate hemihydrate to calcium sulphate dihydrate in the presence of a passive additive. Twenty different mixtures of calcium sulphate hemihydrate, hydroxylapatite (HA) and accelerator (Acc) were evaluated, which had different ratios of hydroxylapatite and accelerator, see Table 3. The setting time was determined by a mechanical test. A metallic rod having a weight of 23 g, a diameter of 10 mm and a length of 35 mm was dropped from a height of 35 mm. The time when the rod did not leave any mark on the sample was registered as the setting time.
-
TABLE 3 CASO4 HA HA ACC IT SI TEST NO. (G) (G) (%) (%) (MIN) (MIN) 1 32 4 10 10 1.5 3.0 2 28 8 20 10 1.5 4.0 3 24 12 30 10 1.5 4.0 4 20 16 40 10 2.0 6.0 5 16 20 50 10 1.5 6.0 6 34 4 10 5 2.0 5.0 7 30 8 20 5 1.5 5.0 8 26 12 30 5 2.5 7.0 9 22 16 40 5 2.5 7.5 10 18 20 50 5 2.0 7.0 11 35 4 10 2.5 1.5 5.0 12 31 8 20 2.5 1.5 5.0 13 27 12 30 2.5 2.0 7.5 14 23 16 40 2.5 2.5 7.5 15 19 20 50 2.5 2.5 10.0 16 35.6 4 10 1 2.5 7.0 17 31.6 8 20 1 3.0 9.0 18 27.6 12 30 1 3.5 10.5 19 23.6 16 40 1 4.0 13.0 20 19.6 20 50 1 4.0 14.5 - Different bi-phasic injectable cements were produced, which were based on α-tricalcium phosphate and α-calcium sulphate hemihydrate.
- The mechanical strength of each cement produced was evaluated with time at 10 hours, 24 hours, 3 days, and 14 days after mixing of the cement with water. The evaluation was performed at the time periods given by means of a cylindrical specimen (d=6 mm, h=12 mm) that had been immersed in a physiological saline solution of 37° C. The results are shown in Table 4 below.
-
TABLE 4 Amount of Compressive Compressive Compressive Compressive α-TCP strength 10 h strength 24 h strength 3 d strength 14 d (wt %) (MPa) ± S.D. (MPa) ± S.D. (MPa) ± S.D. (MPa) ± S.D. 0 11 3.63 7.64 1.41 12.99 2.66 9.66 3.2 20 1.01 0.39 1.69 0.49 3.99 0.35 5.36 0.33 40 0.68 0.25 5.08 1.66 8.82 1.2 9.82 1.86 60 3.58 1.02 5.1 0.91 15.73 5.24 14.13 1.42 80 5.31 1.03 10.72 0.69 21.8 3.41 23.92 3.06 100 6.24 1.48 22.37 6.34 37.99 4.74 33.98 10.37 - The compressive strength was further tested with reference to α-TCP containing less than 20 wt % calcium sulphate hemihydrate (CSH). (CSH was obtained from Bo Ehrlander A B, Gothenborg, Sweden.)
- The two powders were mixed together mechanically during 5 min. Then, the liquid was added to the powder at a liquid to powder (L/P) ratio of 0.32 ml.g−1. The liquid contained 2.5 wt % Na2HPO4 as an accelerator.
- Moulds were then filled and immersed in a saline solution (0.9%) at 37° C. for 7 days. The results are shown in Table 5 below and in
FIG. 1 . - As seen in
FIG. 1 , the compressive strength was drastically increased when the α-TCP content exceeded 80 wt %. -
TABLE 5 Content Compressive Standard No. of of CSH strength Deviation samples (wt %) (MPa) (MPa) tested 0 62.62 7.98 7 5 34.60 9.65 7 10 23.54 10.37 8 15 22.45 5.12 10 - During each of the two setting reactions, crystals are formed when calcium sulphate hemihydrate and calcium phosphate, respectively, react with water in the setting reactions. Initially, crystal nuclei are created and the final crystal structure is then formed by growth from the nuclei. By adding already formed crystals of set material, the nucleation step in the setting process is already completed, which will decrease the time needed to crystallize the material and make it hard. The crystals will grow directly from particles of added calcium sulphate dihydrate and hydroxylapatite, respectively. Thus, these added particles of set material will act as accelerators in the setting reactions.
- The smaller size of accelerator particles added to the material, the more efficient accelerating effect will be obtained because the crystals will grow from the surface of the particles. If the accelerator particles are small, then the surface of the particles will be large per unit of weight.
- When α-CaSO4.2H2O is used as an accelerator it will be more efficient than β-CaSO4.½H2O, when α-CaSO2.½H2O is used as the main component of the material. This could be explained by the crystal shape difference between the two forms of the calcium sulphate. Since the crystals are growing directly from the particle surface of the accelerator, the reaction proceeds faster if the accelerator crystals have exactly the same shape as the crystals that are forming from the main component of the material.
- The effects of the content of calcium sulphate dihydrate on the injection time is shown in
FIG. 2 . In this case the liquid/powder (L/P) ratio is 0.4 ml/g. The limit of injection time was defined when the load reached N, which is comparable to the highest force by hand at which injection was possible. - The effects of the water content and the content of calcium sulphate dihydrate on the setting time is shown in
FIG. 3 , wherein L/P is the liquid-powder ratio (ml/g). The setting time was measured by using Gillmore Needles according to ASTM Standard C266. - In the inventive composition, the form of the calcium sulphate hemihydrate is of importance. α-Calcium sulphate hemihydrate (α-CaSO4.½H2O) is advantageous to use because of its mechanical strength. α-CaSO4.½H2O has a compressive strength of 40.4 MPa compared with 14 MPa for β-α-CaSO4.½H2O.
- The degradation rate of calcium sulphate with 40 wt % hydroxylapatite was investigated. The material was placed in a Simulated Body Fluid as well as muscle pockets in rats. The mechanical strength and size of the block obtained were investigated with time as a biodegradation index.
- Mechanical Testing
- Compressive strength testing was performed using an MTS and Instron 8511.20 testing equipment. After harvesting the materials, the samples were directly placed between self-levelling platens and compressed at 1 mm min−1 until failure at room temperature.
- Volume Measurements
- After the material harvesting, a caliper measured the volume of the block of material.
- In Vitro Study
- Cements of calcium sulphate or calcium sulphate with hydroxylapatite were prepared by mixing with distilled water at L/P ratio of 0.25 ml/g. After mixing the cement was injected into a PFTE mould and allowed to set. The samples were 4 mm in diameter and 8 mm in length. Six cylindrical samples were placed in a Simulated Body Fluid, and the liquid was changed every day. After one week the samples were directly placed between self-levelling platens and subjected to compressive strength testing until failure at room temperature.
- In Vivo Study
- Materials Preparation
- Calcium sulphate hemihydrate (CaSO4.½H2O) was mixed with 40 wt % hydroxylapatite powder (Ca10(PO4)6(OH)2; HA). The mixture of POP-HA was sintered and quenched in air. An accelerator (a calcium sulphate) was added at 0.4 wt % to the POP-HA, and the dry powder material was sterilized by gamma-irradiation.
- A cement was prepared by mixing the powder with distilled water at a L/P ratio of 0.25 ml/g. Materials were prepared, which contained calcium sulphate or calcium sulphate+hydroxylapatite. After mixing, the cement was injected into a PFTE mould and allowed to set. The samples were cylindrical with diameter of 4 mm and height of 8 mm. Once set, the samples are inserted into muscle pockets of rats.
- Animals
- Sprague-Dawley rats weighing around 200 g were used and kept in animal facilities for 1 week before use. The animals were fed a standard laboratory diet. All rats were anesthetized with peritoneal injections of 0.5-0.6 ml of a solution containing 1 ml pentobarbital (60 mg/ml), 2 ml diazepam (5 mg/ml), and 1 ml saline (0.15 M). The implants were inserted in muscles of the rats. Nine rats were used for each period studied. The rats were killed by a peritoneal injection of an overdose of pentobarbital at 1 or 4 weeks after implantation.
- Results
- After one week of incubation the mechanical strength was recorded of the cylindrical samples placed in the Simulated Body Fluid or muscles pockets in rats, respectively. The mechanical strength of the materials had decreased from 35 Mpa to about 5 Mpa both in vitro as well as in vivo. The volume of remaining block was only ⅓ to 1/10 of the original block volume (Table 5).
- After 4 weeks of incubation, the mechanical strength of the materials had totally disappeared, and the rods of calcium sulphate were almost completely absorbed. The calcium sulphate with hydroxylapatite was still present but totally deformed, and the material was surrounded by normal soft tissue. The tissue also penetrated into the materials. Furthermore, the mass of remaining material was larger than the original block implanted.
- Table 6 below shows the volume of remaining cylinder material (Mean±SE) in rat muscles after an incubation of 1 or 4 weeks. The original volume of the cylinder material was 100 mm3. Statistic analysis was performed by using the one way ANOVA method and Student's t-test. All results obtained exhibited a high statistical significance (p<0.0001).
-
TABLE 6 1 week incubation 4 weeks incubation No. of Volume No. of Volume Material samples (mm3) samples (mm3) PoP 9 31.7 ± 3.1 9 1.9 ± 1.5 PoP t HA 9 6.1 ± 1.5 8 159.4 ± 21.7 PoP + HA + 8 9.1 ± 2.0 8 196.0 ± 17.9 Vitamin E - The implanted material comprising calcium sulphate and hydroxylapatite was rapidly degraded within one week in both Simulated Body Fluid and in rats. The rate of degradation was the same in Simulated Body Fluid or muscles pockets, indicating that only one method is needed in order to demonstrate the degradation rate.
- In conclusion, tests of the combined sulphate and phosphate material exhibit biodegradation in vitro and in vivo as well as hardening of both components with good results with reference to injectability and setting.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/219,543 US20090192629A1 (en) | 2000-07-17 | 2008-07-23 | Composition for an injectable bone mineral substitute material |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0002676A SE517168C2 (en) | 2000-07-17 | 2000-07-17 | A composition for an injectable bone mineral replacement material |
SE0002676-5 | 2000-07-17 | ||
PCT/SE2001/001627 WO2002005861A1 (en) | 2000-07-17 | 2001-07-16 | A composition for an injectable bone mineral substitute material |
US10/333,026 US7417077B2 (en) | 2000-07-17 | 2001-07-16 | Composition for an injectable bone mineral substitute material |
US12/219,543 US20090192629A1 (en) | 2000-07-17 | 2008-07-23 | Composition for an injectable bone mineral substitute material |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/333,026 Division US7417077B2 (en) | 2000-07-17 | 2001-07-16 | Composition for an injectable bone mineral substitute material |
PCT/SE2001/001627 Division WO2002005861A1 (en) | 2000-07-17 | 2001-07-16 | A composition for an injectable bone mineral substitute material |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090192629A1 true US20090192629A1 (en) | 2009-07-30 |
Family
ID=20280508
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/333,026 Expired - Fee Related US7417077B2 (en) | 2000-07-17 | 2001-07-16 | Composition for an injectable bone mineral substitute material |
US12/122,873 Abandoned US20080286331A1 (en) | 2000-07-17 | 2008-05-19 | Composition for an injectable bone mineral substitute material |
US12/219,542 Abandoned US20090018667A1 (en) | 2000-07-17 | 2008-07-23 | Composition for an injectable bone mineral substitute material |
US12/219,543 Abandoned US20090192629A1 (en) | 2000-07-17 | 2008-07-23 | Composition for an injectable bone mineral substitute material |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/333,026 Expired - Fee Related US7417077B2 (en) | 2000-07-17 | 2001-07-16 | Composition for an injectable bone mineral substitute material |
US12/122,873 Abandoned US20080286331A1 (en) | 2000-07-17 | 2008-05-19 | Composition for an injectable bone mineral substitute material |
US12/219,542 Abandoned US20090018667A1 (en) | 2000-07-17 | 2008-07-23 | Composition for an injectable bone mineral substitute material |
Country Status (9)
Country | Link |
---|---|
US (4) | US7417077B2 (en) |
EP (1) | EP1301219B1 (en) |
JP (1) | JP5351369B2 (en) |
AT (1) | ATE313344T1 (en) |
AU (2) | AU2001271209B2 (en) |
DE (1) | DE60116098T2 (en) |
ES (1) | ES2252254T3 (en) |
SE (1) | SE517168C2 (en) |
WO (1) | WO2002005861A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120093771A1 (en) * | 2010-10-19 | 2012-04-19 | National Cheng Kung University | Method for preparing a hardened calcium sulfate dihydrate block and use thereof |
WO2012054009A1 (en) | 2010-10-19 | 2012-04-26 | Jiin-Huey Chern Lin | Method for preparing a hardened calcium sulfate dihydrate block and use thereof |
US8662737B2 (en) | 2004-06-22 | 2014-03-04 | Bone Support Ab | Device for producing a hardenable mass |
US9446170B2 (en) | 2013-12-13 | 2016-09-20 | Agnovos Healthcare, Llc | Multiphasic bone graft substitute material |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE520688C2 (en) * | 2000-04-11 | 2003-08-12 | Bone Support Ab | An injectable bone mineral replacement material |
DE10032220A1 (en) | 2000-07-03 | 2002-01-24 | Sanatis Gmbh | Magnesium ammonium phosphate cements, their manufacture and use |
SE517168C2 (en) * | 2000-07-17 | 2002-04-23 | Bone Support Ab | A composition for an injectable bone mineral replacement material |
PT1829565E (en) * | 2001-12-20 | 2010-04-26 | Bone Support Ab | A new bone mineral substitute |
SE522098C2 (en) * | 2001-12-20 | 2004-01-13 | Bone Support Ab | Artificial bone mineral substitute material useful as an X-ray contrast medium comprises ceramic and water soluble non-ionic X-ray contrast agent |
US7273523B2 (en) | 2002-06-07 | 2007-09-25 | Kyphon Inc. | Strontium-apatite-cement-preparations, cements formed therefrom, and uses thereof |
WO2004000374A1 (en) * | 2002-06-19 | 2003-12-31 | Dr. H.C. Robert Mathys Stiftung | Hydraulic cement based on calcium phosphate for surgical use |
FR2850282B1 (en) | 2003-01-27 | 2007-04-06 | Jerome Asius | INJECTABLE IMPLANT BASED ON CERAMIC FOR THE FILLING OF WRINKLES, CUTANEOUS DEPRESSIONS AND SCARS, AND ITS PREPARATION |
US7507257B2 (en) * | 2003-02-04 | 2009-03-24 | Wright Medical Technology, Inc. | Injectable resorbable bone graft material, powder for forming same and methods relating thereto for treating bone defects |
SE0300620D0 (en) * | 2003-03-05 | 2003-03-05 | Bone Support Ab | A new bone substitute composition |
ES2257131B1 (en) * | 2003-10-01 | 2007-07-01 | Universitat Politecnica De Catalunya | MODIFIED CALCIUM PHOSPHATES WITH IRON. |
SE0302983D0 (en) * | 2003-11-11 | 2003-11-11 | Bone Support Ab | Apparatus for providing spongy bone with bone replacement and / or bone strengthening material and associated method |
SE526985C2 (en) * | 2003-11-27 | 2005-11-29 | Doxa Ab | Fixation system for implant elements |
WO2005105170A1 (en) | 2004-04-27 | 2005-11-10 | Kyphon Inc. | Bone substitute compositions and method of use |
US7749268B2 (en) * | 2004-05-26 | 2010-07-06 | Warsaw Orthopedic, Inc. | Methods for treating the spine |
US7473678B2 (en) * | 2004-10-14 | 2009-01-06 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods of use thereof |
US7250550B2 (en) | 2004-10-22 | 2007-07-31 | Wright Medical Technology, Inc. | Synthetic bone substitute material |
US7651701B2 (en) * | 2005-08-29 | 2010-01-26 | Sanatis Gmbh | Bone cement composition and method of making the same |
US8025903B2 (en) | 2005-09-09 | 2011-09-27 | Wright Medical Technology, Inc. | Composite bone graft substitute cement and articles produced therefrom |
BRPI0617086B8 (en) | 2005-09-09 | 2021-06-22 | Agnovos Healtcare Llc | bone graft substitute composite cement and articles originated from it |
US7754005B2 (en) * | 2006-05-02 | 2010-07-13 | Kyphon Sarl | Bone cement compositions comprising an indicator agent and related methods thereof |
WO2007132026A1 (en) * | 2006-05-12 | 2007-11-22 | Martin-Nieto Camacho Christoba | Bone-regenerating substance composed of semi-hydrated calcium sulphate and calcium phosphate |
DK2021043T3 (en) * | 2006-05-26 | 2011-04-04 | Baxter Int | Injectable bone cavity filler |
BRPI0712910B8 (en) * | 2006-05-26 | 2021-05-25 | Baxter Int | multi-component system for an injectable bone augmentation composition, and, injectable bone augmentation composition |
US7507286B2 (en) * | 2006-06-08 | 2009-03-24 | Sanatis Gmbh | Self-foaming cement for void filling and/or delivery systems |
DE102006037362B3 (en) | 2006-08-09 | 2007-09-20 | Heraeus Kulzer Gmbh | Bone-replacement material has calcium carbonate, which is suspended as particulate calcium carbonate in aqueous solution, which contains water soluble haemostatic agent |
US20080063681A1 (en) * | 2006-09-11 | 2008-03-13 | Ebi, L.P. | Therapeutic bone replacement material |
WO2008039382A2 (en) * | 2006-09-21 | 2008-04-03 | Kyphon Sarl | Diammonium phosphate and other ammonium salts and their use in preventing clotting |
US20080195223A1 (en) * | 2006-11-03 | 2008-08-14 | Avram Allan Eddin | Materials and Methods and Systems for Delivering Localized Medical Treatments |
EP1958649A1 (en) * | 2007-02-14 | 2008-08-20 | Graftys | Injectable calcium-phosphate cement releasing a bone resorption inhibitor |
DK2136852T3 (en) * | 2007-03-26 | 2012-04-16 | Baxter Int | Injectable cavity filler for soft tissue augmentation |
US8106109B2 (en) * | 2007-07-20 | 2012-01-31 | Coltene Whaledent Ag | Dental filling material |
US8226719B2 (en) * | 2007-11-14 | 2012-07-24 | Cook Medical Technologies Llc | Method and bone cement substitute kit for stabilizing a collapsed vertebra of a patient |
WO2009104187A2 (en) | 2008-02-20 | 2009-08-27 | Amos Yahav | Bone graft material and uses thereof |
US7968616B2 (en) * | 2008-04-22 | 2011-06-28 | Kyphon Sarl | Bone cement composition and method |
WO2011075580A1 (en) | 2009-12-18 | 2011-06-23 | Howmedica Osteonics Corp. | Post irradiation shelf-stable dual paste direct injectable bone cement precursor systems and methods of making same |
US9180137B2 (en) | 2010-02-09 | 2015-11-10 | Bone Support Ab | Preparation of bone cement compositions |
EP2353619A1 (en) * | 2010-02-09 | 2011-08-10 | Bone Support AB | Preparation of Bone Cement Compositions |
EP2637983B1 (en) | 2010-11-10 | 2018-12-26 | Stryker European Holdings I, LLC | Process for the preparation of a polymeric bone foam |
US8226766B2 (en) * | 2010-12-22 | 2012-07-24 | United States Gypsum Company | Set accelerator for gypsum hydration |
JP5924636B2 (en) * | 2011-04-26 | 2016-05-25 | 公益財団法人神奈川科学技術アカデミー | Cement material manufacturing method and cement manufacturing method |
ES2399273B1 (en) * | 2011-09-13 | 2014-01-28 | Universidad Politécnica De Valencia | ESTUCO FOR THE CONSERVATION AND RESTORATION OF BONE MATERIALS. |
US10806826B2 (en) | 2013-01-09 | 2020-10-20 | Bacterin International, Inc. | Bone graft substitute containing a temporary contrast agent and a method of generating such and a method of use thereof |
CN105120908B (en) * | 2013-02-20 | 2018-04-27 | 骨支撑股份公司 | The improved solidification of hardenable bone substitute |
KR101423129B1 (en) * | 2014-02-26 | 2014-07-25 | 주식회사 오쎄인 | High strength bone alternative synthetic bone for increasing compressive strength and supplementing blood circulation, and method for producing the same |
BR112017020382A2 (en) | 2015-03-23 | 2018-06-05 | Bone Support Ab | ceramic biphasic bone substitute, ceramic biphasic bone substitute hardening paste and kit for its production |
US20170232151A1 (en) * | 2016-02-13 | 2017-08-17 | National Taiwan University | Bioresorbable synthetic bone graft |
GB201704688D0 (en) * | 2017-03-24 | 2017-05-10 | Biocomposites Ltd | Calcicum based clinical material with antimicrobial properties and method of forming for prevention or treatment of infection |
KR102209945B1 (en) * | 2018-08-17 | 2021-02-02 | 주식회사 오스테온 | A powder composition for preparing bone cement providing tunnels for moving bone-forming cells |
CN109701072B (en) * | 2019-01-30 | 2021-09-24 | 中国科学院金属研究所 | Injectable and degradable artificial bone material and preparation method thereof |
CA3134599A1 (en) * | 2019-03-29 | 2020-10-08 | Goodwin Plc | Investment powder |
CN112479735A (en) * | 2020-12-08 | 2021-03-12 | 昆明市延安医院 | CaSO-containing food4beta-TCP composite ceramic material, preparation method and application |
EP4335466A1 (en) | 2022-09-08 | 2024-03-13 | Heraeus Medical GmbH | Composition for the preparation of a bone substitute material, method for the preparation of a pharmaceutical active substance carrier, pharmaceutical active substance carrier and its use |
Citations (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US949163A (en) * | 1909-07-07 | 1910-02-15 | Bridgeport Brass Co | Grease-gun. |
US1644173A (en) * | 1923-02-01 | 1927-10-04 | Bassick Mfg Co | Lubricating apparatus |
US3367783A (en) * | 1966-03-23 | 1968-02-06 | Gerber Prod | Process of preparing a fruit gel |
US3837379A (en) * | 1973-05-14 | 1974-09-24 | East West Med Prod | Irrigator liquid supply system |
US3965910A (en) * | 1975-04-28 | 1976-06-29 | Walpak Company | Urinary irrigation valve |
US4269331A (en) * | 1980-02-15 | 1981-05-26 | Watson John D | Metered dispensing device |
US4496342A (en) * | 1981-03-20 | 1985-01-29 | Surgical Design Corporation | Surge prevention system for an ophthalmic instrument |
US4583974A (en) * | 1984-04-04 | 1986-04-22 | Kokernak Denis T | Syringe for balloon dilation catheters |
US4721390A (en) * | 1984-10-19 | 1988-01-26 | Mit Ab | Method for producing bone cement for fixing prostheses and device for carrying out said method |
US5047030A (en) * | 1987-02-20 | 1991-09-10 | Klaus Draenert | Suction drainage-bone screw |
US5071040A (en) * | 1990-03-09 | 1991-12-10 | Pfizer Hospital Products Group, Inc. | Surgical adhesives mixing and dispensing implement |
US5168757A (en) * | 1990-05-15 | 1992-12-08 | Ryder International Corporation | Fluid displacement and pressurizing device |
US5232024A (en) * | 1991-05-30 | 1993-08-03 | Eli Williams | Slide-valve manifold |
US5262166A (en) * | 1991-04-17 | 1993-11-16 | Lty Medical Inc | Resorbable bioactive phosphate containing cements |
US5269785A (en) * | 1990-06-28 | 1993-12-14 | Bonutti Peter M | Apparatus and method for tissue removal |
US5281265A (en) * | 1992-02-03 | 1994-01-25 | Liu Sung Tsuen | Resorbable surgical cements |
US5403318A (en) * | 1993-01-15 | 1995-04-04 | Boehringer Laboratories, Inc. | Apparatus and method for shaping bone |
US5605885A (en) * | 1988-05-05 | 1997-02-25 | Entremed, Inc. | Method for stimulating the immune system |
US5837752A (en) * | 1997-07-17 | 1998-11-17 | Massachusetts Institute Of Technology | Semi-interpenetrating polymer networks |
US5842786A (en) * | 1997-03-07 | 1998-12-01 | Solomon; Alan | Method and device for mixing medical compositions |
US5997544A (en) * | 1997-05-02 | 1999-12-07 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Process and device for producing sterile-packed bone cement |
US6074358A (en) * | 1995-02-06 | 2000-06-13 | Andrew; Mark S. | Method and apparatus for lenticular liquefaction and aspiration |
US6118043A (en) * | 1991-06-26 | 2000-09-12 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Bone replacement material with FGF |
US6120174A (en) * | 1999-01-14 | 2000-09-19 | Bristol-Myers Squibb | Apparatus and method for mixing and dispensing bone cement |
US6365218B1 (en) * | 2000-02-04 | 2002-04-02 | Abbott Laboratories | Pediatric formula and methods for providing nutrition and improving tolerance |
US6447809B1 (en) * | 1999-05-11 | 2002-09-10 | Metagenics, Inc. | Composition for promoting healthy bone structure |
US20020156483A1 (en) * | 2001-02-15 | 2002-10-24 | Voellmicke John C. | Vertebroplasty injection device and bone cement therefor |
US20020169506A1 (en) * | 2001-05-02 | 2002-11-14 | Asahi Kogaku Kogyo Kabushiki Kaisha | Prosthetic filler for a living body and method of manufacturing the prosthetic filler |
US20030109883A1 (en) * | 2001-12-06 | 2003-06-12 | Hiromi Matsuzaki | Surgical instruments and a set of surgical instruments for use in treatment of vertebral bodies |
US20040006347A1 (en) * | 2002-07-05 | 2004-01-08 | Sproul Michael E. | Ultrasonic cannula system |
US6706273B1 (en) * | 1999-08-14 | 2004-03-16 | Ivoclar Vivadent Ag | Composition for implantation into the human and animal body |
US20040191897A1 (en) * | 2003-03-31 | 2004-09-30 | The Cleveland Clinic Foundation | Apparatus and method for harvesting bone marrow |
US20060122621A1 (en) * | 2004-12-06 | 2006-06-08 | Csaba Truckai | Bone treatment systems and methods |
US7393342B2 (en) * | 2003-05-12 | 2008-07-01 | Stryker Corporation | Bone cement mixing and delivery system including a delivery gun and a cartridge having a piston, the delivery gun configured to release the piston |
US20080318862A1 (en) * | 2003-02-27 | 2008-12-25 | A Enterprises, Inc. | Crosslinkable polymeric materials and their applications |
US7524103B2 (en) * | 2003-11-18 | 2009-04-28 | Boston Scientific Scimed, Inc. | Apparatus for mixing and dispensing a multi-component bone cement |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3475010A (en) * | 1968-04-24 | 1969-10-28 | Prod Res & Chem Corp | Dispensing cartridge for intermixing separate ingredients |
CH608189A5 (en) * | 1974-12-13 | 1978-12-29 | Savac Ag | |
CH626873A5 (en) * | 1977-03-28 | 1981-12-15 | Bracco Ind Chimica Spa | |
IT1207226B (en) | 1979-08-09 | 1989-05-17 | Bracco Ind Chimica Spa | 2,4,6-TRIIODE-ISOPHTHALIC ACID DERIVATIVES, METHOD FOR THEIR PREPARATION AND CONTRAST MEANS THAT CONTAIN THEM. |
US4338925A (en) * | 1979-12-20 | 1982-07-13 | Jo Miller | Pressure injection of bone cement apparatus and method |
DE3206911A1 (en) * | 1982-02-26 | 1983-09-15 | Lohmann Tierernährung GmbH, 2190 Cuxhaven | BIOCHEMICAL ACTIVE SUBSTANCE, THE PRODUCTION THEREOF AND SUBSTANCE CONTAINING THIS ACTIVE SUBSTANCE |
US4439420A (en) | 1982-11-16 | 1984-03-27 | Ethicon, Inc. | Absorbable hemostatic composition |
US4584401A (en) | 1983-10-20 | 1986-04-22 | Biophysica Foundation | Methods and compositions involving polyhydroxylated polyiodo non-ionic contrast media |
US4619655A (en) * | 1984-01-26 | 1986-10-28 | University Of North Carolina | Plaster of Paris as a bioresorbable scaffold in implants for bone repair |
JPS6199623A (en) | 1984-10-18 | 1986-05-17 | High Frequency Heattreat Co Ltd | Quenching method controlled numerically |
US4676655A (en) * | 1985-11-18 | 1987-06-30 | Isidore Handler | Plunger type cartridge mixer for fluent materials |
WO1987005521A1 (en) * | 1986-03-11 | 1987-09-24 | University Of Medicine And Dentistry Of New Jersey | Moldable bone implant material |
US4752479A (en) * | 1986-05-27 | 1988-06-21 | Ciba-Geigy Corporaton | Multi vitamin and mineral dietary supplement with controlled release bioavailable iron |
ES2007350A6 (en) * | 1987-05-29 | 1989-06-16 | Ganadera Union Ind Agro | Food products enriched with nucleosides and/or nucleotides and preparation thereof. |
DE3731542A1 (en) | 1987-09-17 | 1989-03-30 | Schering Ag | NEW DICARBONIC ACID-BIS (3,5-DICARBAMOYL-2,4,6-TRIIOD-ANILIDE), METHOD FOR THE PRODUCTION THEREOF AND THESE CONTAINING X-RAY AGENTS |
GB8724897D0 (en) | 1987-10-23 | 1987-11-25 | Downes S | Material |
JPH0684289B2 (en) | 1987-11-26 | 1994-10-26 | 株式会社トクヤマ | One-paste restoration material |
AU5950790A (en) * | 1989-06-30 | 1991-01-17 | United States Gypsum Company | Calcium sulfate hemihydrate composition having utility in the presence of blood |
GB8919929D0 (en) * | 1989-09-04 | 1989-10-18 | Nycomed As | Compositions |
US5236456A (en) | 1989-11-09 | 1993-08-17 | Osteotech, Inc. | Osteogenic composition and implant containing same |
EP0537180A4 (en) | 1990-05-11 | 1993-04-28 | Lifecore Medical, Inc. | Rapid setting hydroxylapatite and plaster formulation |
US5990382A (en) * | 1990-08-29 | 1999-11-23 | Biomedical Enterprises, Inc. | Method and implant for surgical manipulation of bone |
US6080801A (en) * | 1990-09-13 | 2000-06-27 | Klaus Draenert | Multi-component material and process for its preparation |
US5149368A (en) * | 1991-01-10 | 1992-09-22 | Liu Sung Tsuen | Resorbable bioactive calcium phosphate cement |
US5462722A (en) * | 1991-04-17 | 1995-10-31 | Liu; Sung-Tsuen | Calcium phosphate calcium sulfate composite implant material |
DE69205736T2 (en) * | 1991-06-26 | 1996-06-13 | Nitta Gelatin Kk | Hardenable calcium phosphate-containing material for repairing living hard tissues. |
SE510490C2 (en) * | 1992-02-07 | 1999-05-31 | Scandimed International Ab | Process for producing bone cement and apparatus for carrying out the process |
CA2103683C (en) * | 1992-08-17 | 1998-06-16 | George Weeks | Methods of controlling dust and compositions produced thereby |
IT1256248B (en) | 1992-12-24 | 1995-11-29 | Bracco Spa | WATER INJECTABLE FORMULATIONS FOR RADIODIAGNOSTICS INCLUDING MIXTURES OF IODURATED AROMATIC COMPOUNDS USEFUL AS X-RAY MATTING AGENTS |
SE510491C2 (en) | 1993-08-18 | 1999-05-31 | Coripharm Gmbh & Co | Cement for medical use and manufacture and use of the cement |
US5385887A (en) * | 1993-09-10 | 1995-01-31 | Genetics Institute, Inc. | Formulations for delivery of osteogenic proteins |
US5681873A (en) * | 1993-10-14 | 1997-10-28 | Atrix Laboratories, Inc. | Biodegradable polymeric composition |
US5360823A (en) * | 1993-11-02 | 1994-11-01 | Dawe's Inc. | Anionic salt formulation for milk fever |
US6248110B1 (en) * | 1994-01-26 | 2001-06-19 | Kyphon, Inc. | Systems and methods for treating fractured or diseased bone using expandable bodies |
US6716216B1 (en) * | 1998-08-14 | 2004-04-06 | Kyphon Inc. | Systems and methods for treating vertebral bodies |
DE4409610C3 (en) * | 1994-03-21 | 2001-09-20 | Scandimed Internat Ab Sjoebo | Mixing device |
DE4425218A1 (en) * | 1994-07-16 | 1996-01-18 | Merck Patent Gmbh | Device for mixing and discharging bone cement |
US6075067A (en) * | 1994-08-15 | 2000-06-13 | Corpipharm Gmbh & Co | Cement for medical use, method for producing the cement, and use of the cement |
DE4433201A1 (en) | 1994-09-17 | 1996-03-21 | Merck Patent Gmbh | Process for the production of active ingredient-containing bone cements |
DE4435680A1 (en) * | 1994-10-06 | 1996-04-11 | Merck Patent Gmbh | Porous bone substitute materials |
US5614206A (en) * | 1995-03-07 | 1997-03-25 | Wright Medical Technology, Inc. | Controlled dissolution pellet containing calcium sulfate |
JPH11506659A (en) | 1995-06-06 | 1999-06-15 | オステオジェニックス・インコーポレーテッド | Biocompatible hydroxyapatite formulations and uses thereof |
ATE223734T1 (en) | 1995-12-19 | 2002-09-15 | Bracco Research Sa | COMPOSITIONS CONTAINING TRICODOBENZENE POLYMERS FOR IMAGING THE GASTROINTESTINAL TRACT |
US6596904B1 (en) * | 1996-01-29 | 2003-07-22 | Mallinc Krodt Inc | Process for producing ioversol |
DE19620117C1 (en) | 1996-05-18 | 1997-07-24 | Corimed Kundenorientierte Medi | Preparation of medicinal composition containing calcium sulphate |
FR2749756B1 (en) * | 1996-06-14 | 1998-09-11 | Bioland | PROCESS FOR THE PREPARATION OF AN IMPLANTABLE COMPOSITE MATERIAL, MATERIAL OBTAINED, IMPLANT COMPRISING SUCH MATERIAL, AND IMPLEMENTATION KIT |
US5871549A (en) | 1996-12-12 | 1999-02-16 | Johnson & Johnson Professional, Inc. | Femoral stem with reduced coefficient of friction with respect to bone cement |
US20020076378A1 (en) * | 1997-01-29 | 2002-06-20 | Nycomed Imaging As | Polymers |
US5829875A (en) * | 1997-04-02 | 1998-11-03 | Simpson Strong-Tie Co., Inc. | Combined barrier and mixer assembly for a cylindrical container |
US6071982A (en) * | 1997-04-18 | 2000-06-06 | Cambridge Scientific, Inc. | Bioerodible polymeric semi-interpenetrating network alloys for surgical plates and bone cements, and method for making same |
IT1292037B1 (en) * | 1997-05-30 | 1999-01-25 | Bracco Spa | PROCESS FOR THE PREPARATION OF 5- (ACETYL 62,3-DIIDROXYPROPYL) - AMINO) -N, N'-BIS (2,3-DIIDROXYPROPYL) -2,4,6-TRIIODE-1,3-BENZEN- |
US6048346A (en) * | 1997-08-13 | 2000-04-11 | Kyphon Inc. | Systems and methods for injecting flowable materials into bones |
DE69803398T2 (en) * | 1997-10-07 | 2002-09-26 | Robert Mathys Stiftung Bettlac | HYDRAULIC SURGICAL CEMENT |
US6309420B1 (en) * | 1997-10-14 | 2001-10-30 | Parallax Medical, Inc. | Enhanced visibility materials for implantation in hard tissue |
JP4145490B2 (en) * | 1997-10-20 | 2008-09-03 | ピーアールシー−デソト インターナショナル,インコーポレイティド | Manual dispensing syringe for multi-component substances |
US6440138B1 (en) * | 1998-04-06 | 2002-08-27 | Kyphon Inc. | Structures and methods for creating cavities in interior body regions |
DE19816858A1 (en) | 1998-04-16 | 1999-10-21 | Merck Patent Gmbh | Tricalcium phosphate-containing bio-cement pastes with cohesion promoters |
SE511087C2 (en) * | 1998-05-29 | 1999-08-02 | Bone Support Ab | Process for producing powder component for cement for medical use, use of such powder component and such powder component |
SE9802528D0 (en) | 1998-07-13 | 1998-07-13 | Gs Dev Ab | Bone tissue restoring composition |
WO2000007639A1 (en) * | 1998-08-07 | 2000-02-17 | Tissue Engineering, Inc. | Bone precursor compositions |
DE19853832A1 (en) * | 1998-11-21 | 2000-05-25 | Merck Patent Gmbh | Calcium phosphate cements containing polyalkenoic acids |
US6642285B1 (en) | 1999-02-02 | 2003-11-04 | Robert Mathys Stiftung | Implant comprising calcium cement and hydrophobic liquid |
JP2001104324A (en) * | 1999-10-06 | 2001-04-17 | Ngk Spark Plug Co Ltd | Medicine extruding auxiliary device, and medicine extruding method using the same |
DE19953771C1 (en) * | 1999-11-09 | 2001-06-13 | Coripharm Medizinprodukte Gmbh | Absorbable bone implant material and method for producing the same |
EP1155704A1 (en) * | 2000-01-13 | 2001-11-21 | Chih-I Lin | Orthopedic filling material and method of use thereof |
US6790210B1 (en) * | 2000-02-16 | 2004-09-14 | Trans1, Inc. | Methods and apparatus for forming curved axial bores through spinal vertebrae |
US6723334B1 (en) * | 2000-03-01 | 2004-04-20 | Iowa State University Research Foundation, Inc. | Biologically compatible bone cements and orthopedic methods |
US6652883B2 (en) * | 2000-03-13 | 2003-11-25 | Biocure, Inc. | Tissue bulking and coating compositions |
SE520688C2 (en) * | 2000-04-11 | 2003-08-12 | Bone Support Ab | An injectable bone mineral replacement material |
ES2178556B1 (en) | 2000-06-30 | 2004-07-16 | Universitat Politecnica De Catalunya | CEMENT OF CALCIUM SULPHATE WITH CONTROLLED BIODEGRADATION. |
SE517168C2 (en) | 2000-07-17 | 2002-04-23 | Bone Support Ab | A composition for an injectable bone mineral replacement material |
ITMI20010773A1 (en) * | 2001-04-11 | 2002-10-11 | Chemi Spa | PROCESS FOR THE PRODUCTION OF HIGH PURITY IOEXOLO |
GB0110726D0 (en) * | 2001-05-02 | 2001-06-27 | Biocomposites Ltd | Bone implant composition |
US20030055512A1 (en) * | 2001-05-21 | 2003-03-20 | Genin Francois Y. | Calcium based neutral and bioresorbable bone graft |
US6547432B2 (en) * | 2001-07-16 | 2003-04-15 | Stryker Instruments | Bone cement mixing and delivery device for injection and method thereof |
US20030028251A1 (en) * | 2001-07-30 | 2003-02-06 | Mathews Hallett H. | Methods and devices for interbody spinal stabilization |
US6706069B2 (en) * | 2001-09-13 | 2004-03-16 | J. Lee Berger | Spinal grooved director with built in balloon |
WO2003041753A1 (en) | 2001-11-14 | 2003-05-22 | Ecole Polytechnique Federale De Lausanne (Epfl) | Pasty or liquid multiple constituent compositions for injectable calcium phosphate cements |
PT1829565E (en) | 2001-12-20 | 2010-04-26 | Bone Support Ab | A new bone mineral substitute |
SE522098C2 (en) * | 2001-12-20 | 2004-01-13 | Bone Support Ab | Artificial bone mineral substitute material useful as an X-ray contrast medium comprises ceramic and water soluble non-ionic X-ray contrast agent |
WO2004000374A1 (en) * | 2002-06-19 | 2003-12-31 | Dr. H.C. Robert Mathys Stiftung | Hydraulic cement based on calcium phosphate for surgical use |
US20050287071A1 (en) * | 2002-12-03 | 2005-12-29 | Kyphon Inc. | Formulation for a cement preparation as bone substitute |
ES2269973T3 (en) * | 2003-02-13 | 2007-04-01 | Synthes Ag Chur | INJECTABLE MIXTURE TO REPLACE A BEAR FABRIC. |
SE0300620D0 (en) * | 2003-03-05 | 2003-03-05 | Bone Support Ab | A new bone substitute composition |
US7306786B2 (en) * | 2003-07-28 | 2007-12-11 | Skeletal Kinetics, Llc | Calcium phosphate cements comprising a water-soluble contrast agent |
SE0302983D0 (en) * | 2003-11-11 | 2003-11-11 | Bone Support Ab | Apparatus for providing spongy bone with bone replacement and / or bone strengthening material and associated method |
ES2286713T3 (en) * | 2003-12-01 | 2007-12-01 | Broockeville Corporation N.V. | MIXING AND DISPENSING DEVICE OF TWO COMPONENTS. |
WO2005105170A1 (en) * | 2004-04-27 | 2005-11-10 | Kyphon Inc. | Bone substitute compositions and method of use |
US20050257714A1 (en) * | 2004-05-20 | 2005-11-24 | Constantz Brent R | Orthopedic cements comprising a barium apatite contrast agent |
SE527528C2 (en) * | 2004-06-22 | 2006-04-04 | Bone Support Ab | Apparatus for the preparation of curable pulp and use of the apparatus |
US7776073B2 (en) * | 2004-06-30 | 2010-08-17 | Depuy Spine, Inc. | In-situ formed posterolateral fusion system |
WO2006015302A1 (en) * | 2004-07-29 | 2006-02-09 | X-Sten, Corp. | Spinal ligament modification devices |
-
2000
- 2000-07-17 SE SE0002676A patent/SE517168C2/en not_active IP Right Cessation
-
2001
- 2001-07-16 ES ES01950184T patent/ES2252254T3/en not_active Expired - Lifetime
- 2001-07-16 DE DE60116098T patent/DE60116098T2/en not_active Expired - Lifetime
- 2001-07-16 US US10/333,026 patent/US7417077B2/en not_active Expired - Fee Related
- 2001-07-16 AU AU2001271209A patent/AU2001271209B2/en not_active Ceased
- 2001-07-16 AT AT01950184T patent/ATE313344T1/en not_active IP Right Cessation
- 2001-07-16 AU AU7120901A patent/AU7120901A/en active Pending
- 2001-07-16 EP EP01950184A patent/EP1301219B1/en not_active Expired - Lifetime
- 2001-07-16 WO PCT/SE2001/001627 patent/WO2002005861A1/en active IP Right Grant
- 2001-07-16 JP JP2002511792A patent/JP5351369B2/en not_active Expired - Fee Related
-
2008
- 2008-05-19 US US12/122,873 patent/US20080286331A1/en not_active Abandoned
- 2008-07-23 US US12/219,542 patent/US20090018667A1/en not_active Abandoned
- 2008-07-23 US US12/219,543 patent/US20090192629A1/en not_active Abandoned
Patent Citations (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US949163A (en) * | 1909-07-07 | 1910-02-15 | Bridgeport Brass Co | Grease-gun. |
US1644173A (en) * | 1923-02-01 | 1927-10-04 | Bassick Mfg Co | Lubricating apparatus |
US3367783A (en) * | 1966-03-23 | 1968-02-06 | Gerber Prod | Process of preparing a fruit gel |
US3837379A (en) * | 1973-05-14 | 1974-09-24 | East West Med Prod | Irrigator liquid supply system |
US3965910A (en) * | 1975-04-28 | 1976-06-29 | Walpak Company | Urinary irrigation valve |
US4269331A (en) * | 1980-02-15 | 1981-05-26 | Watson John D | Metered dispensing device |
US4496342A (en) * | 1981-03-20 | 1985-01-29 | Surgical Design Corporation | Surge prevention system for an ophthalmic instrument |
US4583974A (en) * | 1984-04-04 | 1986-04-22 | Kokernak Denis T | Syringe for balloon dilation catheters |
US4721390A (en) * | 1984-10-19 | 1988-01-26 | Mit Ab | Method for producing bone cement for fixing prostheses and device for carrying out said method |
US5047030A (en) * | 1987-02-20 | 1991-09-10 | Klaus Draenert | Suction drainage-bone screw |
US5605885A (en) * | 1988-05-05 | 1997-02-25 | Entremed, Inc. | Method for stimulating the immune system |
US5071040A (en) * | 1990-03-09 | 1991-12-10 | Pfizer Hospital Products Group, Inc. | Surgical adhesives mixing and dispensing implement |
US5168757A (en) * | 1990-05-15 | 1992-12-08 | Ryder International Corporation | Fluid displacement and pressurizing device |
US5269785A (en) * | 1990-06-28 | 1993-12-14 | Bonutti Peter M | Apparatus and method for tissue removal |
US5262166A (en) * | 1991-04-17 | 1993-11-16 | Lty Medical Inc | Resorbable bioactive phosphate containing cements |
US5232024A (en) * | 1991-05-30 | 1993-08-03 | Eli Williams | Slide-valve manifold |
US6118043A (en) * | 1991-06-26 | 2000-09-12 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Bone replacement material with FGF |
US5281265A (en) * | 1992-02-03 | 1994-01-25 | Liu Sung Tsuen | Resorbable surgical cements |
US5403318A (en) * | 1993-01-15 | 1995-04-04 | Boehringer Laboratories, Inc. | Apparatus and method for shaping bone |
US6074358A (en) * | 1995-02-06 | 2000-06-13 | Andrew; Mark S. | Method and apparatus for lenticular liquefaction and aspiration |
US5842786A (en) * | 1997-03-07 | 1998-12-01 | Solomon; Alan | Method and device for mixing medical compositions |
US5997544A (en) * | 1997-05-02 | 1999-12-07 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Process and device for producing sterile-packed bone cement |
US5837752A (en) * | 1997-07-17 | 1998-11-17 | Massachusetts Institute Of Technology | Semi-interpenetrating polymer networks |
US6120174A (en) * | 1999-01-14 | 2000-09-19 | Bristol-Myers Squibb | Apparatus and method for mixing and dispensing bone cement |
US6447809B1 (en) * | 1999-05-11 | 2002-09-10 | Metagenics, Inc. | Composition for promoting healthy bone structure |
US6706273B1 (en) * | 1999-08-14 | 2004-03-16 | Ivoclar Vivadent Ag | Composition for implantation into the human and animal body |
US6365218B1 (en) * | 2000-02-04 | 2002-04-02 | Abbott Laboratories | Pediatric formula and methods for providing nutrition and improving tolerance |
US20020156483A1 (en) * | 2001-02-15 | 2002-10-24 | Voellmicke John C. | Vertebroplasty injection device and bone cement therefor |
US20020169506A1 (en) * | 2001-05-02 | 2002-11-14 | Asahi Kogaku Kogyo Kabushiki Kaisha | Prosthetic filler for a living body and method of manufacturing the prosthetic filler |
US20030109883A1 (en) * | 2001-12-06 | 2003-06-12 | Hiromi Matsuzaki | Surgical instruments and a set of surgical instruments for use in treatment of vertebral bodies |
US20040006347A1 (en) * | 2002-07-05 | 2004-01-08 | Sproul Michael E. | Ultrasonic cannula system |
US20080318862A1 (en) * | 2003-02-27 | 2008-12-25 | A Enterprises, Inc. | Crosslinkable polymeric materials and their applications |
US20040191897A1 (en) * | 2003-03-31 | 2004-09-30 | The Cleveland Clinic Foundation | Apparatus and method for harvesting bone marrow |
US7393342B2 (en) * | 2003-05-12 | 2008-07-01 | Stryker Corporation | Bone cement mixing and delivery system including a delivery gun and a cartridge having a piston, the delivery gun configured to release the piston |
US7524103B2 (en) * | 2003-11-18 | 2009-04-28 | Boston Scientific Scimed, Inc. | Apparatus for mixing and dispensing a multi-component bone cement |
US20060122621A1 (en) * | 2004-12-06 | 2006-06-08 | Csaba Truckai | Bone treatment systems and methods |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8662737B2 (en) | 2004-06-22 | 2014-03-04 | Bone Support Ab | Device for producing a hardenable mass |
US20120093771A1 (en) * | 2010-10-19 | 2012-04-19 | National Cheng Kung University | Method for preparing a hardened calcium sulfate dihydrate block and use thereof |
WO2012054009A1 (en) | 2010-10-19 | 2012-04-26 | Jiin-Huey Chern Lin | Method for preparing a hardened calcium sulfate dihydrate block and use thereof |
CN103096713A (en) * | 2010-10-19 | 2013-05-08 | 陈瑾惠 | Method for preparing a hardened calcium sulfate dihydrate block and use thereof |
US9446170B2 (en) | 2013-12-13 | 2016-09-20 | Agnovos Healthcare, Llc | Multiphasic bone graft substitute material |
US10973949B2 (en) | 2013-12-13 | 2021-04-13 | Agnovos Healthcare, Llc | Multiphasic bone graft substitute material |
Also Published As
Publication number | Publication date |
---|---|
US20040048947A1 (en) | 2004-03-11 |
ES2252254T3 (en) | 2006-05-16 |
DE60116098D1 (en) | 2006-01-26 |
EP1301219A1 (en) | 2003-04-16 |
JP5351369B2 (en) | 2013-11-27 |
SE517168C2 (en) | 2002-04-23 |
WO2002005861A1 (en) | 2002-01-24 |
SE0002676L (en) | 2002-01-18 |
SE0002676D0 (en) | 2000-07-17 |
AU2001271209B2 (en) | 2005-12-15 |
US7417077B2 (en) | 2008-08-26 |
JP2004503332A (en) | 2004-02-05 |
DE60116098T2 (en) | 2006-08-17 |
EP1301219B1 (en) | 2005-12-21 |
ATE313344T1 (en) | 2006-01-15 |
US20080286331A1 (en) | 2008-11-20 |
AU7120901A (en) | 2002-01-30 |
US20090018667A1 (en) | 2009-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7417077B2 (en) | Composition for an injectable bone mineral substitute material | |
CA2487994C (en) | Hydraulic cement based on calcium phosphate for surgical use | |
AU2001271209A1 (en) | A composition for an injectable bone mineral substitute material | |
US9642939B2 (en) | Macroporous and highly resorbable apatitic calcium-phosphate cement | |
CA2518104C (en) | Artificial bone mineral substitute for in vivo hardening | |
US6425949B1 (en) | Hydraulic surgical cement | |
CA2325740A1 (en) | Bio-cements having improved properties | |
Bumgardner et al. | Ceramic composites for bone graft applications | |
Dorozhkin | Self-Setting Formulations Calcium Orthophosphate (CaPO4) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BONESUPPORT NYA AB, SWEDEN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BONESUPPORT AB;REEL/FRAME:024879/0744 Effective date: 20100517 |
|
AS | Assignment |
Owner name: BONE SUPPORT NYA AB, SWEDEN Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF ASSIGNOR FROM "BONESUPPORT AB" TO "BONE SUPPORT AB" AND ASSIGNEE FROM "BONESUPPORT NYA AB" TO "BONE SUPPORT NYA AB" PREVIOUSLY RECORDED ON REEL 024879 FRAME 0744. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNOR'S INTEREST;ASSIGNOR:BONE SUPPORT AB;REEL/FRAME:024973/0863 Effective date: 20100517 |
|
AS | Assignment |
Owner name: BONE SUPPORT AB, SWEDEN Free format text: CHANGE OF NAME;ASSIGNOR:BONE SUPPORT NYA AB;REEL/FRAME:025000/0076 Effective date: 20100427 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |